

Supplementary Figure 1. COVID-19 patient plasma neutralises both SARS-CoV-2 D614 and G614 pseudoviruses. Plasma samples of mild (n=25), moderate (n=19), and severe (n=13) COVID-19 patients at median 31 and 98 days post-illness onset (pio) were incubated with luciferase expressing lentiviruses pseudotyped with SARS-CoV-2 D614 or G614 spike (S) glycoprotein protein for 1 hour prior to infection of CHO-ACE2 cells for 48 hours. Infection levels were determined by luciferase assay, and percentage of neutralisation is presented. Dose-response neutralisation titration curves against **(a)** D614 and **(b)** G614 pseudoviruses at 1:10 to 1:31250 dilutions. Lines represent non-linear regression robust fit and data are shown as mean ± SEM of two independent experiments.

Supplementary Figure 1 Lee *et al.*, 2020



Supplementary Figure 2. COVID-19 patient plasma neutralises both SARS-CoV-2 D614 and G614 pseudoviruses. Plasma samples of mild (n=25), moderate (n=19), and severe (n=13) COVID-19 patients at median 31 and 98 days post-illness onset (pio) were incubated at 1:50 dilution with luciferase expressing lentiviruses pseudotyped with SARS-CoV-2 **(a)** D614 or **(b)** G614 spike (S) glycoprotein protein for 1 hour prior to infection of CHO-ACE2 cells for 48 hours. Infection levels were determined by luciferase assay, and percentage of neutralisation is presented. Data are shown as mean ± SEM of two independent experiments. Dotted line indicates 50% neutralisation.

Supplementary Figure 2 Lee *et al.*, 2020